Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DAY 301

Next Previous
Drug Profile

DAY 301

Alternative Names: CB-002 - Day One Biopharmaceuticals; DAY-301; MTX-13

Latest Information Update: 16 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MabCare Therapeutics
  • Developer Day One Biopharmaceuticals; MabCare Therapeutics
  • Class Alkaloids; Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 31 Jan 2026 Day One Biopharmaceuticals has patent families directed to an ADC linker used in DAY301 and pending applications in the US before January 2026
  • 31 Jan 2026 Day One Biopharmaceuticals has patents covering compositions of matter, methods of use, and synthetic intermediates of DAY 301 in the US and pending applications in the Australia, Brazil, Canada, China, Europe, Hong Kong, India, Israel, Japan, Korea, Mexico, Singapore, South Africa, and Taiwan before January 2026
  • 18 Nov 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in Canada (IV) (NCT06752681)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top